IP Library › Granted Patent US 11,965,885
Granted Patent B2
US 11,965,885 · App. 17/332,178 · Granted Apr 23, 2024

Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens

Inventors: Rachel Sorek (Zafaria, IL); Keren Jakobi (Reut-Maccabim, IL); Pennina Safer (Rechovot, IL); Anat Reiner-Benaim (Binyamina, IL); Irun R. Cohen (Rehovot, IL)
Assignee: Yeda Research and Development Co. Ltd.
G01N33/564G01N33/6854G16B40/20G01N2800/104G16B40/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,965,885
App. No.
17/332,178
Granted
Apr 23, 2024
Kind
B2
Abstract

Methods and kits for diagnosing or monitoring systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing or monitoring SLE in a subject.

Claims (10)

1. A method of detecting the levels of antibodies in a sample of a subject having or suspected of having systemic lupus erythematosus (SLE), the method comprising:

(i) obtaining a serum, plasma, or blood sample from the subject;

(ii) exposing antibodies in the sample to at least four antigens, the antigens comprising single stranded DNA (ssDNA), U1 Small Nuclear Ribonucleoprotein (U1 snRNP), and Ro52, and at least one of: Smith antigen (Sm), Deoxyribonuclease I (DNAse I), Histone III-S, Histone H2A (H2a), Collagen III, and Serum amyloid A apolipoprotein (Apo-SAA); and

(iii) detecting in said sample the levels of antibodies reactive with each of the at least four antigens by quantifying the amount of antigen-antibody complex formed for each antigen, wherein the amount of antigen-antibody complex is indicative of the level of each respective antibody in said sample.

2. The method of claim 1 , comprising detecting the levels of IgG antibodies reactive to ssDNA, U1 snRNP, Sm, Apo-SAA, and Ro52, and levels of IgM antibodies reactive to H2a, in said sample.

3. The method of claim 1 , comprising detecting the levels of IgG antibodies reactive to ssDNA, U1 snRNP, Ro52, Collagen III, and Apo-SAA, and levels of IgM antibodies reactive to Histone III-S, in said sample.

4. The method of claim 1 , comprising detecting the levels of IgG antibodies reactive to ssDNA, Sm, DNAse I, Ro52, and U1 snRNP, and levels of IgM antibodies reactive to Histone III-S, in said sample.

5. The method of claim 1 , wherein said sample is a serum sample.

6. The method of claim 1 , wherein the antigens are provided in the form of an antigen array, or an antigen chip.

7. The method of claim 1 , wherein said sample is a plasma sample.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2021
From: IMMUNARRAY LTD.
To: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Reel/Frame 057130/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2021
From: SOREK, RACHEL; JAKOBI, KEREN; SAFER, PENNINA; REINDER-BENHAIM, ANAT
To: IMMUNARRAY LTD.
Reel/Frame 056911/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2021
From: COHEN, IRUN R.
To: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Reel/Frame 056911/0378 →
Continuity (5)
Continuation 15555258
Provisional Application 62249284 · Nov 1, 2015
Provisional Application 62181231 · Jun 18, 2015
Provisional Application 62126616 · Mar 1, 2015
Related Publication 20220003762A1 · Jan 6, 2022